Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body. Chemical name is (R,S)-2-(3-benzoylphenyl) propionic acid and molecular formula is C 16 H 14 O 3 and structural formula is shown in Fig. 1 . It is a white or off-white, odorless powder, and freely soluble in ethanol, chloroform, acetone, and ether soluble, but practically insoluble in water at 20°C. Ketoprofen is a racemate containing equal (50 : 50) amounts of each enantiomer in commercial pharmaceutical raw material and pharmaceutical dosage forms with only the S enantiomer possessing pharmacological activity, 1) and enantiomeric purity of ketoprofen is determined by capillary electrophoresis.
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2) It is demonstrated 3) that the half dose of dexketoprofen (25 mg, pure S(ϩ)-enantiomer of ketoprofen) and a dose of racemic ketoprofen (50 mg) exhibit similar pain relief effects which are significantly superior to placebo. Some enantiomers can undergo chiral inversion, as hepatic enzymes convert one form of the enantiomer to the other form but the degree of chiral inversion for any drug varies between species and cannot be extrapolated from one species to another. 4) Minor gastrointestinal side effects of ketoprofen were observed and upper gastrointestinal symptoms were more common than lower gastrointestinal symptoms.
b-Cyclodextrin is of cyclic oligosaccharides composed of dextrose units joined through a 1-4 bond with seven dextrose units (Fig. 2) . As discussed by Loftssen and Brewster, 5) b-cyclodextrin is capable of forming inclusion complexes with drugs. These noncovalent, inclusion complexes have physical, chemical, and biological properties that are dramatically different from those of either the parent drug/ligand or cyclodextrin. These complexes are used to enhance solubility and dissolution rate, lower volatility, alter release rates, reduce local irritation, and increase the stability of drugs. 6) Ketoprofen b-cyclodextrin inclusion complexes were firstly reported in the 5th Minutes International Symposium on Cyclodextrins in 1990 to be formulated into tablets, capsules and suppositories 7) and published in 1995. 8) Tablets containing the complexes with analgesic and anti-inflammatory agents were patented in European countries, 9) Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) orally effective in treating fever, pain, and inflammation but gastrointestinal side effects were observed. Preparation of ketoprofen b b-cyclodextrin inclusion complexes was to increase the solubility and reduce the irritation. The complexes were prepared and preliminarily confirmed using X-ray diffraction and dissolution test. Antipyretic, analgesic and anti-inflammatory models were induced by 10% yeast using rabbits, 0.8% acetic acid using mice and 1% carrageenin using rats, respectively. Results showed that the dissolution rate of ketoprofen was significantly improved by complexation. X-Ray diffraction pattern of the complexes exhibited a diffuse pattern that differed from that of physical mixture of ketoprofen and b b-cyclodextrin. Ketoprofen markedly inhibited the fever reactions at a single dose of 2 mg/kg as follows: 64.53% (inhibition rate %) at 1h for ketoprofen, 73.04% at 1 h for ketoprofen b b-cyclodextrin inclusion complexes, respectively. Alleviating pain reaction rates following a single dose of 8 mg/kg at 20 min were 39.25% for the inclusion complexes and 26.72% for ketoprofen, respectively. Inhibition rates to rat edema following a single dose of 5 mg/kg at 1 h were 39.47% for the inclusion complexes and 23.86% for ketoprofen. Results for antipyretic, analgesic and anti-inflammatory activities showed that the rapid and stronger effects were found in the treatment group of ketoprofen b b-cyclodextrin inclusion complexes in comparison with those of free ketoprofen.
Key words ketoprofen; b-cyclodextrin inclusion complex; X-ray diffraction; antipyretic; analgesic; anti-inflammatory animal model antipyretic effects of tablets containing the complexes are unknown. Serial nonsteoidal anti-inflammatory drugs including ketoprofen b-cyclodextrin inclusion complexes were prepared and the solubility of the complexes and affecting factors like pH and temperature were investigated in 1991. 10) Themo-and spectroscopic analyses of ketoprofen b-cyclodextrin inclusion complexes were further studied in 1995. 11) Rekharsky et al. 12) had reported that titration calorimetry and nuclear magnetic resonance (NMR) were used for measurement of aromatic chemicals including phenethylamine, ephedrines and related substances. Rekharsky et al. 13) further reviewed that the most enatiomeric pairs of ligands give only small differences in thermodynamic quantities upon complexation with cyclodextrins and only a small variety of organic substances may probably have chiral discrimination with a exception of atroposomeric (R)-and (S)-1,1Ј-binaphthyl-2,2Ј-diyl hydrogen phosphate. Complexation of ketoprofen with b-cyclodextrin was performed in H 2 O medium (pH) for thermodynamic investigations including complex stability constant, standard free energy, enthalpy, and entropy changes. Schneider et al. 14) reviewed that the 1 H-NMR is used to be used for structure analyses of un-substituted cyclodextrins and 2 dimension (2D) NMR techniques including NOE (Nuclear Overhauser Effect) methods are applied to analyses of substituted cyclodextrins with more complicated spin systems. Our previous papers related to ketoprofen b-cyclodextrin inclusion complexes have reported the following aspects since 1997: (1) absorptions of ketoprofen b-cyclodextrin complexes using in situ rat small intestines 15) ; (2) pharmacokinetics/pharmacodynamics combined modeling in rabbits 16) ; (3) preliminary pharmacological effects in rabbits and rats 17) ; (4) UV, FTIR and 1 H-NMR observations of the complexes which were prepared with grinding and spray-drying methods.
18) Diaz et al. 19) reported the interaction forces involved in the inclusion processes of ketoprofen with several cyclodextrins and assessment of the best cyclodextrin for complexing this anti-inflammatory drug. The pico-and nano-second spectroscopic techniques were used by Monti et al. 20) that the intra-molecular electron transfer and hydrogen abstraction may exist during the complaxation of ketoprofen with b-cyclodextrin and an additional photoreaction was evidenced. Vavia et al. 21) further reported ketoprofen b-cyclodextrin inclusion complexes and confirmed the existence of the complexes by phase solubility method, Fourier transformed infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), and X-ray diffractometry (XRD).
The objectives of preparation of b-cyclodextrin inclusion complexes were to increase the solubility and reduce gastric intestinal irritation of ketoprofen. Nevertheless, the detailed structure information of ketoprofen b-cyclodextrin inclusion complexes and comprehensive pharmacodynamic evaluation following ketoprofen complexation with b-cyclodextrin were unavailable. Our efforts to elucidate the structure of the inclusion complexes using 1 H-NMR and NOE (Nuclear Overhauser Effect) are being undertaken. Aims of present paper were preliminarily to confirm the existence of ketoprofen b-cyclodextrin inclusion complexes prepared with freeze-drying method and study the antipyretic, analgesic and anti-inflammatory activities in animals.
MATERIALS AND METHODS

Preparation of Ketoprofen b b-Cyclodextrin Inclusion
Complexes b-Cyclodextrin (Cyclodextrin Factory of Yunan, China) was dissolved in 20% ethanol-water (v/v) at 60°C and appropriate amount of ketoprofen (Xinan Pharmaceutical Factory, China) dissolved in methanol and then mixed the two solutions together (ketoprofen/b-cyclodextrinϭ1/2, mol/mol). After stirring for 1 h at 60°C, the suspension was freeze-dried and the inclusion complexes were formed. Appropriate amount of the inclusion complexes was washed by ether and filtered. The filtrate was evaporated and re-constituted using methanol for determination of entrapment efficiency at 261 nm of wavelength with ultraviolet spectrophotometer (Analysis Equipment Factory of Shanghai, China).
X-Ray Diffraction Ketoprofen, b-cyclodextrin, ketoprofen b-cyclodextrin complexes and physical mixture of ketoprofen/b-cyclodextrin were determined with X-ray diffraction (D/max-r C, Rigaku, Japan). Parameters for X-ray diffraction were: Cu target, 40 kV of tube voltage, 50 mA of tube electric current, 0.5 degree of emission slit, 0.3 degree of reception slit, 1 degree of defense dispersion slit, 0.02 of step length and 5 degree/min of scanning speed.
Dissolution Rate Dissolution rate was tested using paddle method according to Chinese Pharmacopoeia 2000 Edition (Part II). 22) An aliquot of ketoprofen (50.0 mg) or ketoprofen b-cyclodextrin inclusion complexes (equivalent to 50.0 mg of ketoprofen) was weighed for the test. Medium was water at 37Ϯ0.5°C and the revolution rate was set as 100 revolutions per min. An aliquot of 10 ml of samples were collected at 5, 10, 20, 30, 45, 60, 90, 120 min, respectively, and the same volume of fresh water was supplemented to the dissolution flask in time after sampling. The samples were filtered with micropore filters (0.22 mm) and measured at 261 nm of wavelength using ultraviolet spectrophotometer.
Antipyretic Model Induced by Yeast An aliquot of 3 ml/kg of 10% yeast suspension was subcutaneously injected onto the rabbit back. After 5 h, anus temperature rising was observed and then rabbits were divided into 5 groups. Drugs were orally administered at a single dose, including 0.5% CMC-Na suspension (blank control, nϭ8), 2.0 mg/kg of ketoprofen suspended with 0.5% CMC-Na (positive control, nϭ6), 1.0 mg/kg (2.0 or 4.0 mg/kg) of ketoprofen b-cyclodextrin inclusion complexes suspended with 0.5% CMCNa (nϭ6 for each group). Temperatures were recorded following dosing at 1.0, 2.0, 3.0, and 5.0 h. Increased temperature value was the temperature difference between before and after fever.
Analgesic Model Induced by Acetic Acid Seventy-five Kun-Ming mice (China) were equally divided into 5 groups. Drugs were orally irrigated at a single dose, including 0.5% CMC-Na suspension as a blank control, 8.0 mg/kg of ketoprofen suspended with 0.5% CMC-Na as a positive control, and 4.0 mg/kg (8.0 or 16.0 mg/kg) of ketoprofen b-cyclodextrin inclusion complexes suspended with 0.5% CMC-Na. Volume for gastric irrigation was 20 ml/kg. After 5 h of gastric irrigation, 0.8% acetic acid was peritoneally injected into mice (0.2 ml per mouse). The body twisting numbers of mice induced by acetic acid were recorded within 20 min.
Anti-inflammatory Models Induced by Carrageenin
Rats (250Ϯ5 g) were divided into 5 groups (13 or 14 rats per group), and orally irrigated at a single dose, including 0.5% CMC-Na suspension as a blank control, 5.0 mg/kg of ketoprofen suspended with 0.5% CMC-Na as a positive control, and 5.0 mg/kg (2.5 or 10.0 mg/kg) of ketoprofen b-cyclodextrin inclusion complexes suspended with 0.5% CMC-Na. After 30 min of oral irrigation of drugs, 1% carrageenin was injected into paw aponeurosis of each rat (0.1 ml per rat). The paw volumes before and after inflammation induced by carrageenin were recorded using capillary magnification method. 23) Edema degree was the difference between after and before inflammation.
RESULTS
Entrapment Efficiency of Ketoprofen
There is no more exact method for evaluation of entrapment efficiency of cyclodextrins because the cavity of cyclodextrin is not an occluded capsule with two opens. Entrapment efficiency of ketoprofen was roughly estimated to be 93.5% using "ether wash" method, inferring that a small part of ketoprofen may be drawn out of from cavity of b-cyclodextrin due to the interaction between ketoprofen and ether.
X-Ray Diffraction X-Ray diffraction patterns were shown in Fig. 3 (ketoprofen), Fig. 4 (b-cyclodextrin) , Fig. 5 (freeze-dried ketoprofen b-cyclodextrin inclusion complexes), and Fig. 6 (physical mixture of ketoprofen and b-cyclodextrin). Results indicated that the most of peaks of physical mixture were the superposition of peaks of ketoprofen and b-cyclodextrin. Partial peaks of ketoprofen declined and disappeared, showing that the slight complexation may occur in the process of mixing (Fig. 6) . Whereas, the X-ray diffraction pattern of ketoprofen b-cyclodextrin inclusion complexes was completely different from that of ketoprofen or b-cyclodextrin, demonstrating that a new solid phase formed and showed a diffuse pattern (Fig. 5) .
Dissolution Test Dissolution profiles of ketoprofen powder and ketoprofen b-cyclodextrin inclusion complexes were depicted as Fig. 7 , showing that the dissolution rate of ketoprofen b-cyclodextrin inclusion complexes was 95% at 5 min, whereas that of ketoprofen was 15% at 10 min and 45% at 120 min. It was found that the dissolution rate and extent were significantly improved by the complexation and water solubility was much increased.
Antipyretic, Analgesic and Anti-inflammatory Activities Effect on rabbit fever induced by subcutaneous injection of yeast suspension was described in Table 1 . Result showed that the ketoprofen markedly inhibited the fever reactions at a single dose of 2 mg/kg as follows: 64.53% (inhibition rate %) at 1 h for ketoprofen, 73.0% at 1 h for ketoprofen b-cyclodextrin inclusion complexes, respectively. It was demonstrated that the antipyretic activity of ketoprofen b-cyclodextrin inclusion complexes was higher than that of ketoprofen. The inhibition rates (%) of both ketoprofen and the complexes groups increased to nearly 80%, exhibiting that the ketoprofen powder was also well absorbed but slowly. With regard to the high dose group (4 mg/kg) of ketoprofen b-cyclodextrin inclusion complexes, inhibition rate increased to 88.08% (%) and effect lasted for 5 h. The results from different dose groups showed that the inhibition rate (%) increased with the increased dose.
Analgesic activity of ketoprofen b-cyclodextrin inclusion complexes was shown in Table 2 . Pronounced alleviating pain reactions induced by acetic acid were observed at 10 min and 20 min after oral administration of ketoprofen b-cyclodextrin inclusion complexes at a single dose of 8 mg/kg and the body twisting numbers were markedly lower than those of the same amount of ketoprofen group. In comparison with the inhibition rate of blank control group, those of body twisting numbers at 20 min were 39.25% for ketoprofen b-cyclodextrin inclusion complexes and 26.72% for ketoprofen, respectively. Activity increased with the increased doses, in which the inhibition rate reached to 57.47% after gastric irrigation of ketoprofen b-cyclodextrin inclusion complexes at single dose of 16.0 mg/kg.
Marked inhibition to rat edema induced by carrageenin was found following administration of ketoprofen b-cyclodextrin inclusion complexes at a single dose of 5 mg/kg and the inhibition rates (%) were significantly higher that those of the same amount of ketoprofen at early stage, indicating that the effect of inclusion complexes group acted more rapidly and powerful in comparison with that of positive control group (ketoprofen). The intensity of effect showed a linear relationship with the dose from 2.5 mg/kg to 10.0 mg/kg, the maximal inhibition rate was 62% and effect lasted for 5 h, as described in Table 3 .
DISCUSSION
Crystalline solid of free ketoprofen, b-cyclodextrin or the inclusion complexes has its unique characteristic X-ray powder pattern that was used for the fingerprint characterization of crystalline materials and the determination of structure. The results demonstrated that the diffraction pattern of newly formed inclusion complexes was diffuse due to changed diffraction angles of the structure. Similar phenomena were observed in reported investigations that the peaks of the inclusion complexes were more blunt in compared with those of free drug or free b-cyclodextrin itself. 24, 25) The preliminary confirmation of existence of the inclusion complexes is not enough, therefore 1 H-NMR and NOE (Nuclear Overhauser Effect) are being performed to fully characterize the structure of the inclusion complexes, as mentioned in introduction section.
In present experiments, much improved dissolution rate can be an indirect proof for the complexation and were especially good for the rapid action for alleviating the pain reaction. The phase solubility technique was used for evaluation of the improving solubility efficiency after drug complexation with b-cyclodextrin as reported elsewhere, the dissolution test may be an alternative for achieving the same purpose.
After compleaxation with the b-cyclodextrin, the full evaluation of activities for a chemical entity is necessary, because the activity of the ingredient may be affected by such a binding. In vivo activity studies showed that the antipyretic, analgesic and anti-inflammatory activities were improved at early stage after administration due to the improved solubility and rapid absorption of ketoprofen included in b-cyclodextrin. Our study has verified that the tritium labbeled b-cyclodextrin was absorbed less than 5%ϫ10 Ϫ4 of total amount (data not shown), suggested that b-cyclodextrin was nearly not absorbed. The rapid effects derived from the increased solubility of ketoprofen using the inclusion complexes.
In conclusion, the entrapment efficiency of ketoprofen was 93.5%. Formation of ketoprofen b-cyclodextrin inclusion was preliminarily confirmed using X-ray diffraction and dissolution test, respectively. X-Ray diffraction pattern of ketoprofen b-cyclodextrin inclusion complexes was completely different from that of ketoprofen or b-cyclodextrin, verifying that a new solid phase formed and showed a diffuse pattern. Ketoprofen markedly inhibited the fever reactions at a single dose of 2 mg/kg as follows: 64.53% (inhibition rate %) at 1 h for ketoprofen, 73.04% at 1 h for ketoprofen b-cyclodextrin inclusion complexes, respectively. Alleviating pain reaction rates after a single dose of 8 mg/kg at 20 min were 39.25% for the inclusion complexes and 26.72% for ketoprofen, respectively. Inhibition rates to rat edema following a single dose of 5 mg/kg at 1 h were 39.47% for the inclusion complexes and 23.86% for ketoprofen. Results for antipyretic, analgesic and anti-inflammatory activities showed that the rapid and stronger effects were found in the treatment group of ketoprofen b-cyclodextrin inclusion complexes in comparison with those of free ketoprofen.
